Cover Image
市場調查報告書

The Medicines Company的產品平台分析

The Medicines Company - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256122
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
The Medicines Company的產品平台分析 The Medicines Company - Product Pipeline Review - 2016
出版日期: 2016年05月31日 內容資訊: 英文 61 Pages
簡介

本報告提供The Medicines Company上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

The Medicines Company的基本資料

The Medicines Company概要

  • 主要資訊
  • 企業資料

The Medicines Company:R&D概要

  • 主要的治療範圍

The Medicines Company:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

The Medicines Company:開發中產品概況

  • 位於最終階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請未通過/被撤消的產品/聯合治療模式
  • 位於臨床實驗階段的開發中產品
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式

The Medicines Company:藥物簡介

  • cangrelor
  • oritavancin disphosphate
  • (biapenem + RPX-7009)
  • (RPX-2014 + RPX-7009)
  • MDCO-216
  • Rec Fibrinogen Injectable Hemostat
  • tigecycline

The Medicines Company:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

The Medicines Company:最近的開發平台趨勢

The Medicines Company:暫停中的計劃

The Medicines Company:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • clopidogrel bisulfate
    • MDCO-2010

The Medicines Company:企業發表

The Medicines Company:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08062CDB

Summary

Global Markets Direct's, 'The Medicines Company - Product Pipeline Review - 2016', provides an overview of the The Medicines Company's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by The Medicines Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of The Medicines Company
  • The report provides overview of The Medicines Company including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses The Medicines Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features The Medicines Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for The Medicines Company
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding The Medicines Company's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • The Medicines Company Snapshot
    • The Medicines Company Overview
    • Key Information
    • Key Facts
  • The Medicines Company - Research and Development Overview
    • Key Therapeutic Areas
  • The Medicines Company - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • The Medicines Company - Pipeline Products Glance
    • The Medicines Company - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • The Medicines Company - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • The Medicines Company - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • The Medicines Company - Drug Profiles
    • bivalirudin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cangrelor tetrasodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clevidipine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (meropenem+ vaborbactam [INN])
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABP-700
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDCO-216
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fentanyl
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oritavancin diphosphate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Carboetomidate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Methoxycarbonyl Carboetomidate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Methoxycarbonyl Etomidate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Carbapenemase for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tigecycline
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • The Medicines Company - Pipeline Analysis
    • The Medicines Company - Pipeline Products by Target
    • The Medicines Company - Pipeline Products by Route of Administration
    • The Medicines Company - Pipeline Products by Molecule Type
    • The Medicines Company - Pipeline Products by Mechanism of Action
  • The Medicines Company - Recent Pipeline Updates
  • The Medicines Company - Dormant Projects
  • The Medicines Company - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • The Medicines Company, Key Information
  • The Medicines Company, Key Facts
  • The Medicines Company - Pipeline by Indication, 2016
  • The Medicines Company - Pipeline by Stage of Development, 2016
  • The Medicines Company - Monotherapy Products in Pipeline, 2016
  • The Medicines Company - Combination Treatment Modalities in Pipeline, 2016
  • The Medicines Company - Partnered Products in Pipeline, 2016
  • The Medicines Company - Partnered Products/ Combination Treatment Modalities, 2016
  • The Medicines Company - Pre-Registration, 2016
  • The Medicines Company - Phase III, 2016
  • The Medicines Company - Phase II, 2016
  • The Medicines Company - Phase I, 2016
  • The Medicines Company - IND/CTA Filed, 2016
  • The Medicines Company - Preclinical, 2016
  • The Medicines Company - Pipeline by Target, 2016
  • The Medicines Company - Pipeline by Route of Administration, 2016
  • The Medicines Company - Pipeline by Molecule Type, 2016
  • The Medicines Company - Pipeline Products by Mechanism of Action, 2016
  • The Medicines Company - Recent Pipeline Updates, 2016
  • The Medicines Company - Dormant Developmental Projects,2016
  • The Medicines Company, Other Locations
  • The Medicines Company, Subsidiaries

List of Figures

  • The Medicines Company - Pipeline by Top 10 Indication, 2016
  • The Medicines Company - Pipeline by Stage of Development, 2016
  • The Medicines Company - Monotherapy Products in Pipeline, 2016
  • The Medicines Company - Combination Treatment Modalities in Pipeline, 2016
  • The Medicines Company - Partnered Products in Pipeline, 2016
  • The Medicines Company - Pipeline by Target, 2016
  • The Medicines Company - Pipeline by Route of Administration, 2016
  • The Medicines Company - Pipeline by Molecule Type, 2016
  • The Medicines Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top